Aspira Stock Executives


USD 0.86  0.09  11.69%   

Aspira Womans employes about 106 people. The company is managed by 23 executives with total tenure of roughly 216 years, averaging almost 9.0 years of service per executive having 4.61 employees per reported executive. Examination of Aspira Womans management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Aspira Womans Health future performance.
Please continue to Trending Equities.
  Bart Friedman  Chairman
Lead Independent Vice Chairman of the Board
  Scott Carmilani  Chairman
Chairman, CEO and President and Chairperson of Executive Committee
  Wesley Dupont  President
Executive Vice President General Counsel

Aspira Womans Return on Sales


Aspira Womans Management Team Effectiveness

Aspira Womans Health has Return on Asset of (48.25) % which means that on every $100 spent on asset, it lost $48.25. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (94.53) %, meaning that it generated no profit with money invested by stockholders. Aspira Womans management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -145.7. The current Return on Average Assets is estimated to decrease to -0.66. Aspira Womans Total Assets Per Share are most likely to slightly decrease in the upcoming years. The last year's value of Total Assets Per Share was reported at 0.37. The current Asset Turnover is estimated to increase to 0.18, while Total Assets are projected to decrease to roughly 32.6 M.

Aspira Womans Quarterly Total Assets

30.86 Million

The current Issuance Purchase of Equity Shares is estimated to increase to about 52.8 M, while Weighted Average Shares is projected to decrease to roughly 90.7 M.

Aspira Womans Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aspira Womans insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aspira Womans' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aspira Womans insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Aspira Womans Health Benchmark Summation

The output start index for this execution was zero with a total number of output elements of sixty-one. Aspira Womans Health Price Series Summation is a cross summation of Aspira Womans price series and its benchmark/peer.

Aspira Womans Notable Stakeholders

An Aspira Womans stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aspira Womans often face trade-offs trying to please all of them. Aspira Womans' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aspira Womans' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Bart Friedman - Lead Independent Vice Chairman of the BoardProfile
Scott Carmilani - Chairman, CEO and President and Chairperson of Executive CommitteeProfile
Wesley Dupont - Executive Vice President General CounselProfile
Susan Chmieleski - President of Allied World North American HealthcareProfile
Marshall Grossack - Executive Vice President Chief ActuaryProfile
Frank DOrazio - President of Underwriting and Global RiskProfile
John Gauthier - Executive Vice President Chief Investment Officer; President of Allied World Financial Services, Inc. and Allied World Financial Services, LtdProfile
Dale Chow - Senior Vice President - Professional Lines of Allied World BermudaProfile
Kent Ziegler - Senior Vice President - Finance, Chief Accounting OfficerProfile
John Bender - President of Allied World Reinsurance Management CompanyProfile
Louis Iglesias - President of North America for Allied World Assurance Company (US) Inc and President of North America for Allied World National Assurance CompanyProfile
Julian James - President of Allied World Assurance Company (Europe) LimitedProfile
Thomas Bradley - CFO and Executive VPProfile
John McElroy - COOProfile
Eric Schwartz - Independent DirectorProfile
James Duffy - Independent DirectorProfile
Patrick SaintAignan - Independent DirectorProfile
Samuel Weinhoff - Independent DirectorProfile
Barbara Alexander - Independent DirectorProfile
Patricia Guinn - DirectorProfile
Fiona Luck - DirectorProfile
Giuseppe Montefinese - IR Contact OfficerProfile
Sarah Doran - IR Contact OfficerProfile

About Aspira Womans Management Performance

The success or failure of an entity such as Aspira Womans Health often depends on how effective the management is. Aspira Womans management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aspira management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aspira management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Return on Investment(135.04) (145.70) 
Return on Average Assets(0.61) (0.66) 
Return on Average Equity(0.76) (0.81) 
Return on Invested Capital(57.01) (58.51) 
Return on Sales(4.64) (5.01) 
Aspira Womens Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. Aspira Womens Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas. Aspira Womans operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 106 people.
The data published in Aspira Womans' official financial statements usually reflect Aspira Womans' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Aspira Womans Health. For example, before you start analyzing numbers published by Aspira accountants, it's critical to develop an understanding of what Aspira Womans' liquidity, profitability, and earnings quality are in the context of the Pharmaceutical Products space in which it operates.
Please note, the presentation of Aspira Womans' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aspira Womans' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Aspira Womans' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aspira Womans Health. Please utilize our Beneish M Score to check the likelihood of Aspira Womans' management to manipulate its earnings.

Aspira Womans Workforce Analysis

Traditionally, organizations such as Aspira Womans use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aspira Womans within its industry.

Aspira Womans Manpower Efficiency

Return on Aspira Womans Manpower

Revenue Per Employee75.9 K
Revenue Per Executive313.5 K
Net Loss Per Employee316.3 K
Net Loss Per Executive1.5 M
Working Capital Per Employee88.6 K
Working Capital Per Executive408.5 K
Today, most investors in Aspira Womans Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aspira Womans' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Aspira Womans per employee as a starting point in their analysis.

Per Employee

Aspira Womans Per Employee Growth Over Time

Net Income Per Employee


Aspira Womans Net Income Per Employee is most likely to increase significantly in the upcoming years. The last year's value of Net Income Per Employee was reported at (293,167)

Revenue Per Employee


Aspira Womans Revenue Per Employee is most likely to decrease significantly in the upcoming years. The last year's value of Revenue Per Employee was reported at 63,074
Please continue to Trending Equities. Note that the Aspira Womans Health information on this page should be used as a complementary analysis to other Aspira Womans' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Aspira Stock analysis

When running Aspira Womans Health price analysis, check to measure Aspira Womans' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aspira Womans is operating at the current time. Most of Aspira Womans' value examination focuses on studying past and present price action to predict the probability of Aspira Womans' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aspira Womans' price. Additionally, you may evaluate how the addition of Aspira Womans to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Bond Directory
Find actively traded corporate debentures issued by US companies
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Is Aspira Womans' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aspira Womans. If investors know Aspira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aspira Womans listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
86.4 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Aspira Womans Health is measured differently than its book value, which is the value of Aspira that is recorded on the company's balance sheet. Investors also form their own opinion of Aspira Womans' value that differs from its market value or its book value, called intrinsic value, which is Aspira Womans' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aspira Womans' market value can be influenced by many factors that don't directly affect Aspira Womans' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aspira Womans' value and its price as these two are different measures arrived at by different means. Investors typically determine Aspira Womans value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aspira Womans' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.